Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Psychopharmacology

• Publication date

  2017-06-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00213-017-4664-zPMID 28631100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives.

  2017cited by this paper
• One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug

  2016cited by this paper
• Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.

  2015cited by this paper
• Environmental Enrichment Duration Differentially Affects Behavior and Neuroplasticity in Adult Mice.

  2015cited by this paper
• SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl/6 mice.

  2014cited by this paper
• Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment

  2014cited by this paper
• 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice

  2012cited by this paper
• Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice.

  2012cited by this paper
• Current perspectives on pharmacotherapy of Alzheimer's disease

  2011cited by this paper
• Acetylcholine and memory: a long, complex and chaotic but still living relationship.

  2011cited by this paper
• Involvement of the cholinergic system in conditioning and perceptual memory.

  2011cited by this paper
• Combination treatments in Alzheimer’s disease: risks and benefits

  2010cited by this paper
• Cholinesterase inhibitors and beyond.

  2009cited by this paper
• The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs -- Methods of Behavior Analysis in Neuroscience

  2009cited by this paper
• Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid Secretion

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice.

  2008cited by this paper
• Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory.

  2007cited by this paper
• VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.

  2007cited by this paper
• 5-Hydroxytryptamine 1A Receptor Blockade Facilitates Aversive Learning in Mice: Interactions with Cholinergic and Glutamatergic Mechanisms

  2006cited by this paper
• Current pharmacotherapy for Alzheimer's disease.

  2006cited by this paper
• Nicotinic cholinergic modulation: galantamine as a prototype.

  2006cited by this paper
• Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia.

  2006cited by this paper
• Different molecular cascades in different sites of the brain control memory consolidation.

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice

  2005cited by this paper
• The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory.

  2004cited by this paper
• Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist β-carbolines

  2004cited by this paper
• The serotonin 5-HT4 receptor and the amyloid precursor protein processing.

  2003cited by this paper
• BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse

  2003cited by this paper
• Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats.

  2003cited by this paper
• A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

  2003cited by this paper
• SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties

  2002cited by this paper
• RS 67333 and D-cycloserine accelerate learning acquisition in the rat.

  2001cited by this paper
• Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies.

  2001cited by this paper
• Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors.

  2001cited by this paper
• Differential modulation of the 5-HT(4) receptor agonists and antagonist on rat learning and memory.

  2000cited by this paper
• Role of 5-HT4 receptors in the mouse passive avoidance test.

  1998cited by this paper
• BIMU1 increases associative memory in rats by activating 5-HT4 receptors.

  1997cited by this paper
• The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation.

  1997cited by this paper
• Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

  1996cited by this paper
• D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats.

  1993cited by this paper
• Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice.

  1989cited by this paper
• A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

  1988cited by this paper
• Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes.

  1981cited by this paper
• Dissociation of disinhibitory effects of scopolamine: strain and task factors.

  1975cited by this paper

• Past, present, and future of serotonin-targeting therapeutics for Alzheimer's Disease: perspectives from DNA methylation.

  2025cites this paper
• Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective

  2025cites this paper
• Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease

  2025cites this paper
• Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics

  2024cites this paper
• Genetic Background Influence on Hippocampal Synaptic Plasticity: Frequency-Dependent Variations between an Inbred and an Outbred Mice Strain

  2023cites this paper
• Donecopride, a Swiss army knife with potential interest against Alzheimer's disease

  2021cites this paper
• Combination of MAP6 deficit, maternal separation and MK801 in female mice: A 3-hit animal model of neurodevelopmental disorder with cognitive deficits.

  2021cites this paper
• Galantamine nanoparticles outperform oral galantamine in an Alzheimer's rat model: pharmacokinetics and pharmacodynamics.

  2021cites this paper
• Case studies on computer-based identification of natural products as lead molecules

  2020cites this paper
• Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease

  2020cites this paper
• Antipsychotic lurasidone: Behavioural and pharmacokinetic data in C57BL/6 mice.

  2020cites this paper
• Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

  2020cites this paper
• Donecopride, a Swiss army knife with potential against Alzheimer's disease

  2019cites this paper
• Design of Natural‐Product‐Inspired Multitarget Ligands by Machine Learning

  2019cites this paper
• Monoamines and their derivatives on GPCRs: potential therapy for Alzheimer's Disease.

  2019cites this paper
• Distinct Co-Modulation Rules of Synapses and Voltage-Gated Currents Coordinate Interactions of Multiple Neuromodulators

  2018cites this paper
• Distinct co-modulation rules of synaptic and voltage-gated currents coordinates interactions of multiple neuromodulators

  2018cites this paper
• Co-modulation of synapses and voltage-gated ionic currents by combined actions of multiple neuromodulators follow distinct rules

  2018cites this paper